320.37
price up icon1.50%   4.73
after-market Handel nachbörslich: 320.37
loading
Schlusskurs vom Vortag:
$315.64
Offen:
$315.77
24-Stunden-Volumen:
481.52K
Relative Volume:
0.98
Marktkapitalisierung:
$14.45B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
12.78
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
+3.77%
1M Leistung:
+6.52%
6M Leistung:
-13.53%
1J Leistung:
+19.67%
1-Tages-Spanne:
Value
$311.62
$320.91
1-Wochen-Bereich:
Value
$302.79
$320.91
52-Wochen-Spanne:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Firmenname
United Therapeutics Corp
Name
Telefon
(301) 608-9292
Name
Adresse
1000 SPRING ST, SILVER SPRING, MD
Name
Mitarbeiter
1,305
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
UTHR's Discussions on Twitter

Vergleichen Sie UTHR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
320.37 13.93B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.33 49.79B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
167.14 72.11B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.76 4.24M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.80 45.01B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.53 19.43B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-25 Herabstufung Wells Fargo Overweight → Equal Weight
2025-04-21 Hochstufung BofA Securities Underperform → Neutral
2024-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-02-12 Hochstufung Goldman Sell → Neutral
2024-02-05 Eingeleitet Leerink Partners Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2022-12-06 Eingeleitet UBS Buy
2022-12-05 Eingeleitet Goldman Sell
2022-10-11 Eingeleitet Morgan Stanley Overweight
2022-09-20 Bestätigt BofA Securities Underperform
2022-09-19 Fortgesetzt Wedbush Outperform
2022-02-11 Eingeleitet BTIG Research Neutral
2021-07-14 Hochstufung Argus Hold → Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-02-01 Hochstufung H.C. Wainwright Neutral → Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-06-25 Bestätigt H.C. Wainwright Neutral
2020-03-10 Hochstufung Jefferies Hold → Buy
2020-02-27 Hochstufung Cowen Market Perform → Outperform
2020-01-31 Hochstufung JP Morgan Neutral → Overweight
2019-12-03 Eingeleitet BofA/Merrill Underperform
2019-08-01 Hochstufung Jefferies Underperform → Hold
2019-08-01 Hochstufung Ladenburg Thalmann Neutral → Buy
2019-07-01 Hochstufung Credit Suisse Neutral → Outperform
2019-05-17 Hochstufung UBS Sell → Neutral
2019-05-09 Hochstufung Credit Suisse Underperform → Neutral
2018-10-12 Hochstufung Standpoint Research Hold → Buy
2018-08-08 Herabstufung Credit Suisse Neutral → Underperform
2018-04-03 Hochstufung Credit Suisse Underperform → Neutral
2018-02-22 Bestätigt Barclays Underweight
2018-01-18 Fortgesetzt Credit Suisse Underperform
2017-12-27 Bestätigt Wedbush Outperform
2017-04-27 Bestätigt Wedbush Outperform
2017-03-30 Eingeleitet UBS Sell
2017-03-16 Eingeleitet Credit Suisse Underperform
Alle ansehen

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

pulisher
07:11 AM

Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360

07:11 AM
pulisher
07:23 AM

Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo

07:23 AM
pulisher
May 27, 2025

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga

May 27, 2025
pulisher
May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025
pulisher
May 26, 2025

Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com

May 26, 2025
pulisher
May 24, 2025

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey

May 24, 2025
pulisher
May 24, 2025

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World

May 24, 2025
pulisher
May 23, 2025

FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

May 23, 2025
pulisher
May 23, 2025

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewswire Inc.

May 23, 2025
pulisher
May 23, 2025

Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World

May 23, 2025
pulisher
May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025
pulisher
May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025
pulisher
May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025
pulisher
May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025
pulisher
May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025
pulisher
May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025
pulisher
May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha

May 05, 2025
pulisher
May 02, 2025

US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex

May 02, 2025
pulisher
May 02, 2025

United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

BofA raises United Therapeutics stock target to $321 - Investing.com Australia

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

Avepoint, Meta, United Therapeutics - TradingView

May 01, 2025
pulisher
May 01, 2025

United Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Reports Strong Q1 2025 Growth - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

United Therapeutics Corp. Reports Record Revenue Growth - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com

Apr 30, 2025

Finanzdaten der United Therapeutics Corp-Aktie (UTHR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic RDY
$14.75
price up icon 1.30%
$123.66
price up icon 0.51%
drug_manufacturers_specialty_generic HCM
$13.86
price up icon 4.76%
$8.83
price up icon 2.79%
$17.53
price down icon 3.42%
Kapitalisierung:     |  Volumen (24h):